Home Cart Sign in  
Chemical Structure| 1609960-30-6 Chemical Structure| 1609960-30-6

Structure of TH287
CAS No.: 1609960-30-6

Chemical Structure| 1609960-30-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TH287 is a selective MTH1 inhibitor with IC50 value of 0.8 nM.

Synonyms: TH287

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of TH287

CAS No. :1609960-30-6
Formula : C11H10Cl2N4
M.W : 269.13
SMILES Code : NC1=NC(C2=CC=CC(Cl)=C2Cl)=CC(NC)=N1
Synonyms :
TH287
MDL No. :MFCD29035111
InChI Key :URWCXPXBBITYLR-UHFFFAOYSA-N
Pubchem ID :73441664

Safety of TH287

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of TH287

DNA

Isoform Comparison

Biological Activity

Target
  • MTH1

    MTH1, IC50:0.8 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
PC3 20 μmol/L 1 hour Evaluate the inhibitory effect of TH287 on 8-oxodGTPase activity PMC7079300
H1563 20 μmol/L 1 hour Evaluate the inhibitory effect of TH287 on 8-oxodGTPase activity PMC7079300
A549 20 μmol/L 1 hour Evaluate cytotoxicity, showing low cytotoxicity PMC7079300
H23 20 μmol/L 1 hour Evaluate the inhibitory effect of TH287 on 8-oxodGTPase activity PMC7079300
U2OS 20 μmol/L 1 hour Evaluate the inhibitory effect of TH287 on 8-oxodGTPase activity PMC7079300
MCF-7 cells 10 μM 24 hours K-145 reduced nuclear S1P, almost completely blocked H3-K9ac, HIF1α associated spheroid formation, and enhanced dead cells PMC8755538
U2OS cells 10 μM 24 hours Significantly inhibited U2OS cell growth PMC8755538
HT1080 cells 10 μM 24 hours To evaluate the toxicity of CBL0137 on HT1080 cells and p53 activation. Results showed that CBL0137 caused growth arrest at 0.5-1 μM but did not induce senescence markers. PMC8755538
Glioblastoma cells (U251MG) 0.5–15 nM 30 minutes Evaluate the binding affinity of [3H]TH287 to MTH1, showing Kd of 1.97±0.18 nM and Bmax of 2676±122 fmol/mg protein. PMC7700685
MRC-5 (normal lung fibroblasts) 10 μM 24 hours TH287 did not significantly induce apoptosis in MRC-5 cells PMC5903006
A549 (wildtype p53) 10 μM 24 hours TH287 did not significantly induce apoptosis in A549 cells PMC5903006
4T1 cells 16 µg/mL 4 hours To evaluate the cellular uptake and antitumor effect of PP@T, results showed that PP@T significantly enhanced oxidative stress and apoptosis under ultrasound irradiation. PMC10254276
H522 (p53-mutated) 10 μM 24 hours TH287 induced apoptosis in H522 cells but did not significantly increase oxidative DNA damage levels PMC5903006
H23 (p53-mutated) 10 μM 24 hours TH287 induced apoptosis in H23 cells and significantly increased oxidative DNA damage levels PMC5903006
HeLa cells 3 μM 18 hours To evaluate the ability of BSA–RuII(CO)2 complex to release CO in HeLa cells, results showed a significant increase in intracellular fluorescence indicating CO release. PMC4876372

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice HT1080 xenograft model Peritoneal injection 6 mg/kg Every 2 days for 16 days Evaluate the antitumor effect of TH287 in vivo PMC8755538
BALB/c mice 4T1 tumor model Tail vein injection 200 µL (TH287 = 300 µM) Two treatments, 7 days apart, lasting 14 days Evaluate the anti-tumor effect of TH287 in vivo, results showed TH287 synergized with photodynamic therapy to significantly inhibit tumor growth. PMC10254276

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.72mL

0.74mL

0.37mL

18.58mL

3.72mL

1.86mL

37.16mL

7.43mL

3.72mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories